Synthesis of Two Novel Homologous Polyphosphoesters Containing Aminophosphonate Units and Cytotoxicity of Some Low-Molecular and Polymeric Aminophosphonate Derivatives

Table 1

In vitro cytotoxicity (mean IC₅₀ values, [µM] ± SD) of the tested compounds and the referent drug cisplatin against the human leukemic lines HL-60, SKW-3, REH, and K-562.

Compounds	IC50 (μM)
	HL-60 (APML)	SKW-3 (CLL)	REH (ALL)	K-562 (CML)
S-1	47.7 ± 6.9	57.2 ± 4.6	19.8 ± 2.7	80.8 ± 11.4
S-2	37.3 ± 4.6	34.3 ± 7.1	18.3 ± 3.2	89.7 ± 9.1
A-3	35.6 ± 6.1	37.0 ± 5.6	30.5 ± 7.8	>200
A-4	21.2 ± 4.4	8.4 ± 1.5	14.1 ± 1.9	18.7 ± 4.9
A-5	76.8 ± 12.9	76.3 ± 7.9	114.8 ± 14.7	139.1 ± 8.1
A-6	64.1 ± 9.8	51.4 ± 7.3	42.8 ± 6.9	47.3 ± 6.5
A-5a	30.2 ± 2.1	10.5 ± 2.5	21.4 ± 0.7	58.6 ± 2.0
A-5b	30.3 ± 2.1	20.5 ± 2.0	17.6 ± 0.8	79.7 ± 3.3
B-6	139.1 ± 11.3	187.2 ± 14.4	165.9 ± 21.5	>200
P-8	2.1 ± 0.6	3.1 ± 1.2	7.9 ± 1.4	35.6 ± 7.3
P-9	5.5 ± 1.2	5.4 ± 1.2	16.8 ± 1.2	24.8 ± 1.1
P-10	49.4 ± 7.3	38.5 ± 4.3	98.7 ± 8.8	163.0 ± 22.3
P-11	116.9 ± 10.4	61.1 ± 9.2	113.4 ± 10.5	>200
P-12	40.1 ± 7.6	29.5 ± 5.2	33.8 ± 6.4	26.9 ± 5.9
Cisplatin	8.1 ± 1.7	11.2 ± 0.8	17.2 ± 2.1	18.6 ± 3.9

APML: acute promyeloid leukemia; CLL: chronic lymphocytic leukemia; ALL: acute lymphoid leukemia; CML: chronic myelocytic leukemia.